PHOENIX, Feb. 8, 2021 /PRNewswire/ — (OTC-CELZ) Inventive Medical Know-how Holdings Inc. introduced at present recruitment of Dr. Caigan Du, Affiliate Professor on the College of British Columbia to the Firm’s Scientific Advisory Board.
Dr. Du is a prime researcher within the space of molecular and immunological understanding of kidney failure and transplant rejection. Dr. Du is funded by quite a few nationwide and worldwide organizations together with the Kidney Basis and the Canadian Institutes of Well being Analysis.
“I’m honored to work with Inventive Medical Know-how Holdings on this fascinating area of leveraging reprogrammed immune cells for regenerating injured kidneys.” Mentioned Dr. Du. “To this point folks take into consideration regenerative drugs and immunology as separate fields. It is extremely thrilling to contemplate the likelihood that immune cells can act as a catalyst for regenerative processes: that is the idea of the ImmCelz® product.”
ImmCelz® is a personalised cell remedy generated by incubation of affected person cells with allogeneic JadiCell stem cells underneath proprietary circumstances. The JadiCell possess potent capability to reprogram the immune system, as exemplified partially by their capability to considerably prolong survival of COVID sufferers in an FDA double blind, placebo managed, medical trial1. ImmCelz® has been demonstrated efficient in animal fashions of rheumatoid arthritis2, liver failure3, stroke4, kind 1 diabetes5 and kidney failure6. Scientific research recommend ImmCelz® features via secretion of a essentially essential molecule known as Hepatocyte Development Issue7, in addition to stimulation of T regulatory cells, a kind of immune system cell that suppresses pathological immunity8.
“As a clinical-stage biotechnology firm, having already commercialized different stem cell merchandise, we perceive the important thing to any success is predicated on the power to draw scientific key opinion leaders.” Mentioned Timothy Warbington, President and CEO of Inventive Medical Know-how Holdings. “Dr. Du is a visionary and pioneer in understanding of kidney illnesses and we wholeheartedly sit up for him becoming a member of our scientific advisory board.”
The Advisory Board of Inventive Medical Know-how Holdings contains internationally famend neurologist Santosh Kesari MD, Ph.D, the previous head of cardiology at Cedar Sinai Medical Heart Timothy Henry, MD and our Director Dr. Amit Patel, inventor of the JadiCell and the primary doctor to have implanted stem cells into the human coronary heart.
About Inventive Medical Know-how Holdings
Inventive Medical Know-how Holdings, Inc. is a business stage biotechnology firm specializing in regenerative drugs/stem cell expertise within the fields of immunotherapy, urology, neurology and orthopedics and is listed on the OTC underneath the ticker image CELZ. For additional details about the corporate, please go to www.creativemedicaltechnology.com.
Ahead Wanting Statements
OTC Markets has not reviewed and doesn’t settle for accountability for the adequacy or accuracy of this launch. This information launch could include forward-looking statements together with however not restricted to feedback relating to the timing and content material of upcoming medical trials and laboratory outcomes, advertising efforts, funding, and so on. Ahead-looking statements handle future occasions and circumstances and, due to this fact, contain inherent dangers and uncertainties. Precise outcomes could differ materially from these presently anticipated in such statements. See the periodic and different experiences filed by Inventive Medical Know-how Holdings, Inc. with the Securities and Alternate Fee and obtainable on the Fee’s web site at www.sec.gov.
1 Umbilical cord mesenchymal stem cells for COVID–19 acute respiratory distress syndrome: A double–blind, phase 1/2a, randomized controlled trial – Lanzoni – – STEM CELLS Translational Medicine – Wiley Online Library
2 Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz® Immunotherapy Product in Rheumatoid Arthritis Model | BioSpace
3 Creative Medical Technology Holdings Announces Reversion of Liver Failure Using ImmCelz® Personalized Cellular Immunotherapy in Preclinical Model | Nasdaq
4 Creative Medical Technology Holdings Identifies Mechanism of Action of ImmCelz® Stroke Regenerative Activity (prnewswire.com)
5 Creative Medical Technology Holdings Announces Positive Data and Patent Filing Using ImmCelz® to Treat Type 1 Diabetes (prnewswire.com)
6 Creative Medical Technology Holdings Files Patent based on Positive Data on Renal Failure using ImmCelz® Regenerative Immunotherapy (prnewswire.com)
7 Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz® Therapeutic Activity (apnews.com)
8 Creative Medical Technology Holdings Identifies Mechanism of Action of ImmCelz® Stroke Regenerative Activity (prnewswire.com)
SOURCE Inventive Medical Know-how Holdings, Inc.